Salud financiera de hoja de balance de MoonLake Immunotherapeutics

Salud financiera controles de criterios 6/6

MoonLake Immunotherapeutics tiene un patrimonio de los accionistas total de $552.4M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $564.1M y $11.7M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$547.05m
Patrimonio	US$552.39m
Total pasivo	US$11.73m
Activos totales	US$564.12m

Actualizaciones recientes sobre salud financiera

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

May 14

We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn

Jan 29

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

Oct 16

Recent updates

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

May 14

MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3

Feb 26

We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn

Jan 29

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

Oct 16

Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics

Jul 26

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($553.6M) de MLTX superan a sus pasivos a corto plazo ($8.9M).

Pasivo a largo plazo: Los activos a corto plazo de MLTX ($553.6M) superan a sus pasivos a largo plazo ($2.8M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: MLTX está libre de deudas.

Reducción de la deuda: MLTX no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: MLTX tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: MLTX tiene suficiente cash runway para más de 3 años si el flujo de caja libre sigue creciendo a tasas históricas de 4.7% cada año

Salud financiera de hoja de balance de MoonLake Immunotherapeutics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

Recent updates

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from Both FDA and EMA on Path for the Phase 3 Program for the Nanobody Sonelokimab in Psoriatic Arthritis

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

MoonLake Immunotherapeutics, Annual General Meeting, Jun 05, 2024

MoonLake Immunotherapeutics, Annual General Meeting, Jun 05, 2024

New major risk - Revenue and earnings growth

Moonlake Immunotherapeutics to Present MIRA Trial Data of Nanobody Sonelokimab in Hidradenitis Suppurativa as A Late Breaker At the AAD Annual Meeting 2024

MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn

High number of new and inexperienced directors

Chief Financial Officer notifies of intention to sell stock

New major risk - Shareholder dilution

New minor risk - Share price stability

Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation

MoonLake Immunotherapeutics Announces the Full Dat Datasets from its 24-Week MIRA Clinical Trial, Establishing the Nanobody(R) Sonelokimab as Highly Promanded Therapeutics for Hidradenitis Suppurativa

Moonlake Immunotherapeutics Ag Announces Phase 2 Mira Primary Analysis Trial Results for Nanobody®? Sonelokimab in Hidradenitis Suppurativa to Be Presented At the European Academy of Dermatology and Venereology Congress

Price target increased by 12% to US$67.91

Price target increased by 12% to US$60.60

Price target increased by 9.4% to US$58.10

New major risk - Financial position

New major risk - Share price stability

Price target increased by 34% to US$43.63

Price target increased by 8.4% to US$32.67

MoonLake Immunotherapeutics AG Completes Patient Enrollment and Randomization Ahead of Schedule in A Phase 2 Trial of the Nanobody(R) Sonelokimab in Moderate-To-Severe Hidradenitis Suppurativa

Moonlake Immunotherapeutics Screens First Patient in Phase 2 Study of the Nanobody® Sonelokimab in Active Psoriatic Arthritis

Moonlake Immunotherapeutics to Initiate Global Phase 2 Study of the Nanobody Sonelokimab in Patients with Active Psoriatic Arthritis

Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics

MoonLake Immunotherapeutics Starts Phase 2 Trial of the Nanobody® Sonelokimab in Patients with Moderate-To-Severe Hidradenitis Suppurativa

MoonLake Immunotherapeutics Announces the Publication of New Long-Term Disease Control Data from A Phase 2B Psoriasis Trial of the Nanobody® Sonelokimab

No independent directors

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera